These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17593207)

  • 1. A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation.
    Van den Eynden GG; Colpaert CG; Couvelard A; Pezzella F; Dirix LY; Vermeulen PB; Van Marck EA; Hasebe T
    Histopathology; 2007 Oct; 51(4):440-51. PubMed ID: 17593207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer.
    Van den Eynden GG; Van der Auwera I; Van Laere SJ; Trinh XB; Colpaert CG; van Dam P; Dirix LY; Vermeulen PB; Van Marck EA
    J Pathol; 2007 Sep; 213(1):56-64. PubMed ID: 17674348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia and breast cancer: prognostic and therapeutic implications.
    Lundgren K; Holm C; Landberg G
    Cell Mol Life Sci; 2007 Dec; 64(24):3233-47. PubMed ID: 17957335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer.
    Van den Eynden GG; Smid M; Van Laere SJ; Colpaert CG; Van der Auwera I; Bich TX; van Dam P; den Bakker MA; Dirix LY; Van Marck EA; Vermeulen PB; Foekens JA
    Clin Cancer Res; 2008 May; 14(10):2944-52. PubMed ID: 18483361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.
    Zhang XH; Huang DP; Guo GL; Chen GR; Zhang HX; Wan L; Chen SY
    BMC Cancer; 2008 Jan; 8():4. PubMed ID: 18190720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
    Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients.
    Colpaert C; Vermeulen P; van Beest P; Goovaerts G; Weyler J; Van Dam P; Dirix L; Van Marck E
    Histopathology; 2001 Oct; 39(4):416-25. PubMed ID: 11683944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications.
    Mohammed RA; Ellis IO; Elsheikh S; Paish EC; Martin SG
    Breast Cancer Res Treat; 2009 Jan; 113(2):261-73. PubMed ID: 18293084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells in breast cancer.
    Ignatiadis M; Georgoulias V; Mavroudis D
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):55-60. PubMed ID: 18197007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory breast cancer: current understanding.
    Dirix LY; Van Dam P; Prové A; Vermeulen PB
    Curr Opin Oncol; 2006 Nov; 18(6):563-71. PubMed ID: 16988576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
    Gadducci A; Tana R; Cosio S; Genazzani AR
    Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer.
    Donnem T; Al-Saad S; Al-Shibli K; Delghandi MP; Persson M; Nilsen MN; Busund LT; Bremnes RM
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6649-57. PubMed ID: 18006765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms.
    Mohammed RA; Ellis IO; Lee AH; Martin SG
    Histopathology; 2009 Jul; 55(1):1-9. PubMed ID: 19016903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder.
    Fernández MI; Bolenz C; Trojan L; Steidler A; Weiss C; Alken P; Grobholz R; Michel MS
    Eur Urol; 2008 Mar; 53(3):571-8. PubMed ID: 17804149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer.
    Li X; Cao X; Li X; Zhang W; Feng Y
    Cancer Sci; 2007 Oct; 98(10):1592-6. PubMed ID: 17651454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients.
    Gazic B; Pizem J; Bracko M; Cufer T; Borstnar S; Pohar-Marinsek Z; Us-Krasovec M
    Cytopathology; 2008 Oct; 19(5):294-302. PubMed ID: 18070112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up.
    Evans AJ; Rakha EA; Pinder SE; Green AR; Paish C; Ellis IO
    J Med Screen; 2007; 14(4):210-4. PubMed ID: 18078567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.